Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Phase 2 Interventional Results available

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

NCT00827359
View directory record Official record
Conditions
Renal Cell Carcinoma, Renal Cancer
Interventions
Everolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PRISM Race and Communication Pilot RCT

NCT04915079
View directory record Official record
Conditions
Discrimination, Racial, Communication, Chronic Illness, Bias, Racial
Interventions
Promoting Resilience in Stress Management (PRISM)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

Chronic Effects of DBS in Parkinson's Disease and Dystonia

NCT01934296
View directory record Official record
Conditions
Parkinson's Disease, Isolated Dystonia
Interventions
Activa PC+S
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 25, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional

Management of Dyssynergic Defecation

NCT07225803
View directory record Official record
Conditions
Dyssynergic Defecation, Constipation
Interventions
Biofeedback, Inspiratory muscle training (IMT)
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

The Impact of IV Acetaminophen on Pain After Appendectomy for Perforated Appendicitis

NCT02881996
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
IV tylenol, No IV tylenol, Ketorolac
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 25, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Results available

Usability Evaluation of the Safer Seat

NCT07011446
View directory record Official record
Conditions
Impaired Mobility, Impaired Balance
Interventions
Safer Seat Usability Trial
Device
Lead sponsor
Julie Faieta
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional

Low Dose Radiotherapy for Osteoarthritis

NCT07715188
View directory record Official record
Conditions
Osteoarthitis
Interventions
Low Dose Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

CART-19 Post-ASCT for Multiple Myeloma

NCT02794246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CART-19 cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

NCT03719300
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
inodiftagene vixteplasmid
Drug
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

NCT02768792
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse
Interventions
pembrolizumab,
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 25, 2026, 2:37 PM EDT
Active, not recruiting Phase 1 Interventional

Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study

NCT03794011
View directory record Official record
Conditions
Neural Tube Defects
Interventions
fetoscopy
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Stanford, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04501614
View directory record Official record
Conditions
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
Interventions
Ponatinib, Chemotherapy Agents
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System

NCT02136004
View directory record Official record
Conditions
Surgical Wound
Interventions
Closer VSS
Device
Lead sponsor
Rex Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Sacramento, California • Englewood, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 25, 2026, 2:37 PM EDT
Not listed Phase 2 Interventional

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

NCT04169347
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Oxaliplatin
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • New Haven, Connecticut • Miami Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effectiveness of the Safe at Home Program

NCT04163549
View directory record Official record
Conditions
Family Functioning, Domestic Violence, Child Abuse
Interventions
Safe at Home
Behavioral
Lead sponsor
International Rescue Committee
Other
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 25, 2026, 2:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

NCT00586443
View directory record Official record
Conditions
Solid Tumors
Interventions
bevacizumab, everolimus, panitumumab
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace

NCT02951143
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
SPECTRUM cigarettes, SPECTRUM cigarettes between
Drug
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)

NCT01467817
View directory record Official record
Conditions
Overweight, Obese, Spinal Cord Injury
Interventions
Lifestyle Intervention, Exercise Control
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional Results available

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

NCT00199381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 25, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and CT-011 for Resected Pancreatic Cancer

NCT01313416
View directory record Official record
Conditions
Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer, Pancreas Cancer
Interventions
CT-011, Gemcitabine
Biological · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 25, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

NCT01989143
View directory record Official record
Conditions
Healthy
Interventions
PF-06480605, Placebo
Drug
Lead sponsor
Telavant, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 25, 2026, 2:37 PM EDT